Actively Recruiting
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Led by University Health Network, Toronto · Updated on 2026-02-17
40
Participants Needed
1
Research Sites
83 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.
CONDITIONS
Official Title
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Recipient of a lung transplant.
- Confirmed CMV viremia with a viral load of 1000 IU/mL or higher.
- Receiving or have started standard antiviral treatment within the past 72 hours as decided by the treating physician.
You will not qualify if you...
- Renal failure with creatinine clearance less than 15 mL/min or requiring dialysis.
- Severe liver impairment (Child-Pugh Class C).
- Currently participating in another interventional clinical trial.
- Receiving a combined transplant such as heart-lung or lung-liver.
- Known allergy or contraindication to antiviral medications used in the study.
- Known resistance to antiviral drugs.
- Taking cyclosporin, pimozide, or ergot alkaloids due to interactions with letermovir.
- Receiving or expected to receive CMV immunoglobulin or IVIG during the initial 3-week treatment period.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Actively Recruiting
Research Team
A
Atul Humar, MD, FRCPC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here